Vicore Pharma to Present at Upcoming Investor Conferences

STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following investor conferences:

• TD Cowen 46^th Annual Health Care Conference
  Location: Boston, USA
  Format: Presentation and 1×1 meetings
  Presentation Date and Time: Wednesday, March 4 at 1:50 PM EST
  Webcast: Link
  Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms

• Leerink Partners Global Healthcare Conference 2026
  Location: Miami, USA
  Format: Presentation and 1×1 meetings
  Presentation Date and Time: Monday, March 9 at 11:20 AM EST
  Webcast: Link
  Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms

• 2026 Jefferies Biotech on the Beach Summit
  Location: Miami, USA
  Format: 1×1 meetings
  Date: Tuesday, March 10
  Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms

• Sweden Life Science Day 2026
  Location: Gothenburg, Sweden
  Format: Presentation
  Presentation Date and Time: Wednesday, March 4 at 9:15 AM CET
  Participant: Hans Jeppsson, CFO

For more information, please contact:
Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.

Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com

Attachments
Vicore Pharma to Present at Upcoming Investor Conferences

SOURCE: Vicore Pharma Holding